Form 8-K - Current report:
SEC Accession No. 0001213900-25-032299
Filing Date
2025-04-16
Accepted
2025-04-15 21:20:12
Documents
16
Period of Report
2025-04-11
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0238488-8k_denali.htm   iXBRL 8-K 48672
2 AMENDMENT TO AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION ea023848801ex3-1_denali.htm EX-3.1 4978
3 PRESS RELEASE, DATED APRIL 14, 2025 ea023848801ex99-1_denali.htm EX-99.1 8528
  Complete submission text file 0001213900-25-032299.txt   300081

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE deca-20250411.xsd EX-101.SCH 4172
5 XBRL DEFINITION FILE deca-20250411_def.xml EX-101.DEF 27297
6 XBRL LABEL FILE deca-20250411_lab.xml EX-101.LAB 37878
7 XBRL PRESENTATION FILE deca-20250411_pre.xml EX-101.PRE 25917
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0238488-8k_denali_htm.xml XML 7467
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 25841053
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)